Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study

A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,

. 2016 ; 34 (3) : 419-24. [pub] 20150607

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17001129
E-zdroje Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem

BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001129
003      
CZ-PrNML
005      
20170117124458.0
007      
ta
008      
170103s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00345-015-1611-7 $2 doi
024    7_
$a 10.1007/s00345-015-1611-7 $2 doi
035    __
$a (PubMed)26049866
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vidlar, Ales $u Department of Urology, University Hospital, Olomouc, Czech Republic.
245    10
$a Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study / $c A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,
520    9_
$a BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a následné studie $7 D005500
650    12
$a ovoce $7 D005638
650    _2
$a lidé $7 D006801
650    _2
$a symptomy dolních močových cest $x etiologie $x patofyziologie $x terapie $7 D059411
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fytoterapie $x metody $7 D008517
650    _2
$a prášky, zásypy, pudry $x terapeutické užití $7 D011208
650    _2
$a hyperplazie prostaty $x komplikace $x patofyziologie $x terapie $7 D011470
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a močení $x fyziologie $7 D014554
650    12
$a Vaccinium macrocarpon $7 D029799
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Vostalova, Jitka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Fromentin, Emilie $u NATUREX-DBS, 375 Huyler Street, South Hackensack, NJ, USA. e.fromentin@naturex.com.
700    1_
$a Roller, Marc $u NATUREX SA, 250 Rue Pierre Bayle, 84911, Avignon, France.
700    1_
$a Simanek, Vilím $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
773    0_
$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 34, č. 3 (2016), s. 419-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26049866 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170117124604 $b ABA008
999    __
$a ok $b bmc $g 1180269 $s 961696
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 $c 3 $d 419-24 $e 20150607 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...